† PEG-Naloxol (NKTR-118) in Phase II clinical trials. Clinical benefit has already been demonstrated with polymer–drug conjugates bearing classical chemotherapeutic agents. The future of ...

As we are living in a changing society and life expectancy has been continuously increasing, human pathologies related to aging, such as musculoskeletal disorders, arthritis, nonhealing wounds or ...